What Pharvaris does

Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead asset, deucrictibant, is being advanced in two distinct formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks, and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks. The company is also pursuing the ultra-rare indication of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Phase 3 RAPIDe-3 reported positive topline data in December 2025, with median time to symptom relief of 1.28 hours versus over 12 hours on placebo, a 92.8% End of Progression response rate versus 60.9% on placebo, and approximately 92% average reduction in attack rates observed in the CHAPTER-1 open-label extension for prophylaxis. An NDA submission for deucrictibant IR is planned for 1H2026, and the Phase 3 CHAPTER-3 prophylaxis study remains ongoing.

Pharvaris is incorporated in the Netherlands as Pharvaris N.V., with its principal operating entity, Pharvaris GmbH, located in Zug, Switzerland. The corporate structure also includes operating subsidiaries in Leiden, the Netherlands, and in Delaware, USA (Lexington, MA), where U.S. commercial activities are being built. The company is publicly listed on NASDAQ under the ticker PHVS and was founded in 2015 by Berndt Modig (current CEO), Anne Lesage (Chief Early Development Officer), Jochen Knolle, and Luc Dochez. Leadership has been deliberately constructed from executives with direct HAE drug development experience, including former senior roles at Jerini AG (originator of icatIbant/Firazyr), Takeda/Shire (TAKHZYRO), Genzyme, and Prosensa.

The business model is a pre-commercial biopharmaceutical model: the company generates no current revenue and recorded a €176 million net loss in 2025, financed entirely through equity capital. To date, Pharvaris has raised over $1 billion cumulatively, including a $70M private placement (June 2023), a $300M underwritten offering (December 2023), a $201.2M public offering (July 2025), a $175M public offering (April 2026), and two May 2026 offerings totaling $247.3M, with Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acting as joint book-running managers on multiple transactions. The company held €292M in cash at the end of 2025 and €247M at Q1 2026, with runway extended into 2028. Upon regulatory approval, Pharvaris plans to commercialize through specialty pharmacy networks (e.g., Accredo, Orsini), specialty distributors, and direct outreach to allergy/immunology specialists and HAE treatment centers, targeting a global HAE patient population estimated at roughly 7,000-15,000 in the U.S., 9,000-15,000 in the EU, and 2,500-4,500 in Japan.

Name

Pharvaris

Legal name

Pharvaris N.V.

Website

https://pharvaris.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists (deucrictibant) for on-demand and prophylactic treatment of hereditary angioedema (HAE) and acquired angioedema, targeting a global rare-disease patient population.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

akta.pro primary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

akta.pro secondary industries

Lead Optimization & Preclinical Candidate Selection (HLAIALAB), Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF)

Keywords

• Oral bradykinin antagonists
• Hereditary angioedema therapy
• Rare disease biopharmaceuticals
• Small molecule drug development
• Angioedema prophylaxis treatment

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales (Projected): Pre-revenue biopharmaceutical company with no current sales. Expected to generate revenue from commercialization of deucrictibant products for HAE and AAE-C1INH treatment once regulatory approvals are obtained. NDA submission for deucrictibant IR on-demand treatment planned for 1H2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Pharvaris develops oral small-molecule bradykinin B2 receptor antagonists (deucrictibant) for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead drug candidate is being advanced in two formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks.

Product overview

Pharvaris is developing deucrictibant, a novel oral bradykinin B2 receptor antagonist, in two distinct formulations: the immediate-release (IR) capsule (PHVS416) for on-demand treatment of acute HAE attacks, and the extended-release (XR) tablet (PHVS719) for prophylactic prevention of HAE attacks. Both formulations target the same underlying mechanism but are optimized for different treatment approaches—rapid onset for acute attacks versus sustained daily coverage for prevention.

Differentiator

Problem solved

Functional benefit

Brands

• Deucrictibant: Novel, potent, oral small-molecule bradykinin B2 receptor antagonist for treatment and prevention of HAE attacks
• PHVS416
• PHVS719

Products and services

• Deucrictibant Immediate-Release (IR) Capsule (PHVS416) Oral immediate-release capsule formulation of deucrictibant designed for on-demand treatment of acute hereditary angioedema (HAE) attacks, achieving therapeutic exposure within 15-30 minutes. Phase 3 RAPIDe-3 trial demonstrated median time to symptom relief of 1.28 hours versus over 12 hours for placebo.
• Deucrictibant Extended-Release (XR) Tablet (PHVS719) Oral extended-release tablet formulation of deucrictibant designed for once-daily prophylactic prevention of hereditary angioedema (HAE) attacks, maintaining sustained therapeutic exposure over 24 hours from day one. CHAPTER-1 open-label extension demonstrated approximately 92% average reduction in attack rates.

Quantifiable outcome

• Median time to symptom relief of 1.28 hours vs. over 12 hours for placebo (Phase 3 RAPIDe-3)
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• U.S. Hereditary Angioedema Association (HAEA)coreOthersPharvaris is committed to strong collaboration with the HAEA patient organization, working closely with the organization to support people living with HAE and their families through education, awareness, and research initiatives.
• HAE International (HAEi)coreOthersPharvaris supports HAE International's efforts to provide resources, education, and support to people living with HAE globally, collaborating on initiatives to amplify efforts and information to even more patients.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BioCryst Pharmaceuticals: BioCryst markets Orladeyo (berotralstat), the first FDA-approved oral prophylactic therapy for hereditary angioedema. As a direct competitor in the oral HAE space, it is the most relevant comparable for Pharvaris's deucrictibant franchise.
• KalVista Pharmaceuticals: KalVista is developing sebetralstat, an oral on-demand HAE therapy in late-stage clinical trials. It is the closest direct head-to-head competitor to Pharvaris's PHVS416 on-demand program in mechanism, indication, and stage of development.
• Pharming Group: Pharming markets Ruconest, a recombinant C1 esterase inhibitor for acute HAE attacks. It is a direct therapeutic-area peer competing for the same HAE on-demand patient population that deucrictibant PHVS416 targets.

Broad incumbents

• Takeda Pharmaceutical: Takeda acquired Shire's HAE franchise (TAKHZYRO/lanadelumab, Cinryze, Firazyr) and is the market-leading player in HAE prophylaxis. Pharvaris's leadership includes the former global program lead for TAKHZYRO, making Takeda the dominant incumbent Pharvaris is positioning to displace.
• CSL Behring: CSL Behring markets Haegarda (subcutaneous C1-INH) and Berinert (C1-INH) for HAE prophylaxis and acute treatment. As a major rare-disease incumbent, it represents the plasma-derived C1-INH replacement standard against which Pharvaris's oral B2 antagonist must compete.
• Sanofi: Sanofi Genzyme historically commercialized Firazyr (icatibant, a bradykinin B2 antagonist) for acute HAE attacks. Although Firazyr is now generic, Sanofi remains the originator of the B2-receptor antagonist class that deucrictibant builds upon.
• Regeneron Pharmaceuticals: Regeneron develops antibody-based therapies for rare inflammatory and immunology indications. While not a direct HAE competitor today, it is a comparable late-stage clinical-to-commercial biopharma model with deep experience in specialty/rare-disease launches Pharvaris aims to replicate.
• Vertex Pharmaceuticals: Vertex has built a profitable rare-disease specialty franchise through CFTR modulators and is expanding into other rare diseases. It serves as a relevant comparable for a late-stage small-molecule rare-disease company approaching first commercial launch.

Emerging players

• Intellia Therapeutics: Intellia is developing NTLA-2002, an in vivo CRISPR/Cas9 gene-editing therapy targeting kallikrein for HAE. It represents a potential future disruptive modality (one-time treatment) overlapping with Pharvaris's prophylactic and on-demand HAE programs.

Others

• Shire (now Takeda) / Jerini AG heritage companies: Jerini AG originally developed icatibant (Firazyr), and several Pharvaris founders and executives came from Jerini/Prosensa. These heritage relationships are not active direct peers but underpin the comparable scientific lineage behind deucrictibant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/pharvaris
• Facebookfacebook.com/pharvaris
• LinkedInlinkedin.com/company/pharvaris

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries5 records

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharvaris